StockData
BeOne Medicines Ltd. logo

BeOne Medicines Ltd.

ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$361.27−9.06 (-2.45%)

Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –

BeOne Medicines BRUKINSA — Europe Net Product Revenue by Quarter

BRUKINSA — Europe Net Product Revenue ($M) ($M)

QuarterlyAnnual

BeOne Medicines BRUKINSA — Europe Net Product Revenue: $196M in Q2 2026, up 30.0% from a year earlier. That is the highest of the 13 quarters on record here.

Latest, Q2 2026
196
Period ended Jun 30, 2026
Change on a year earlier
+30.0%
151 in Q2 2025
History
13 quarters
Since Q1 2023
Sources
10
Documents cited below

Where the Q2 2026 figure comes from

“BRUKINSA sales in the EU totaled $195.6 million in the second quarter, compared to $150.5 million in the prior-year period, representing growth of 30.0%, driven by continued gains in market share across all major markets, including Germany, Italy, Spain, France and the UK.”

Source: Form 10-Q (filed 2026-08-05) ↗

Reported in Form 10-Q / 10-K MD&A.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedBRUKINSA — Europe Net Product Revenue ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026196+30.0%Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 2026182+57.4%Form 10-Q (filed 2026-05-06) ↗
Q4 2025Dec 31, 2025167+47.2%Form 10-K (filed 2026-02-26) ↗
Q3 2025Sep 30, 2025163+67.7%Form 10-Q (filed 2025-11-06) ↗
Q2 2025Jun 30, 2025151+84.9%Form 10-Q (filed 2025-08-06) ↗
Q1 2025Mar 31, 2025116+73.5%Form 10-Q (filed 2025-05-07) ↗
Q4 2024Dec 31, 2024113–Form 10-K (filed 2025-02-27) ↗
Q3 2024Sep 30, 202497.3+216.9%Form 10-Q (filed 2024-11-12) ↗
Q2 2024Jun 30, 202481.4+209.5%Form 10-Q (filed 2024-08-07) ↗
Q1 2024Mar 31, 202466.8+242.6%Form 10-Q (filed 2024-05-08) ↗
Q3 2023Sep 30, 202330.7–Form 10-Q (filed 2024-11-12) ↗
Q2 2023Jun 30, 202326.3–Form 10-Q (filed 2024-08-07) ↗
Q1 2023Mar 31, 202319.5–Form 10-Q (filed 2024-05-08) ↗

Breakdown

What makes up BRUKINSA — Europe Net Product Revenue

Cite this data

StockData. (2026). BeOne Medicines BRUKINSA — Europe Net Product Revenue ($M), quarterly Q1 2023–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod-brukinsa-eu

See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.